key: cord-0954756-zu93fiio
authors: Montravers, Philippe; de Tymowski, Christian; Assadi, Maksud; Yung, Sonia; Kantor, Elie
title: Just a little bit more patience…
date: 2020-05-13
journal: Anaesth Crit Care Pain Med
DOI: 10.1016/j.accpm.2020.05.004
sha: 61bad6d6ad0af1b975597440e4e553863bf0d1d3
doc_id: 954756
cord_uid: zu93fiio

nan

Since the first cases of unexplained pneumonia occurred in China in November 2019, a new coronavirus, SARS-CoV-2, has officially been identified as the source of the global pandemic of coronavirus disease 2019 . Its explosive growth is not only putting healthcare systems under pressure but also physicians' understanding, with more than 7,000 published references since January 2020 (https://www.ncbi.nlm.nih.gov/pubmed/). The number and pace of publications focusing on the treatment of COVID-19 is equally impressive, reaching more than 2,000 articles, mostly represented by case reports, case series, observational cohorts, small clinical trials, expert opinions, review articles and recommendations of learning societies.

The review of Sanders et al. published on April 13, 2020 in the JAMA [1] is a well-documented work, with the screening of more than 1,300 articles published over the last months [1] . At the beginning of April 2020, more than 100 trials analysing pharmacological therapies for COVID-19 in adult patients were recorded on ClinicalTrials.gov, but no published randomised clinical trials have yet been published. The authors drive the reader through repurposed drugs, including chloroquine and hydroxychloroquine, two agents used for malaria (prevention and treatment) and chronic inflammatory diseases (treatment); old antiviral agents such as lopinavir/ritonavir, used for HIV, and oseltamivir, used for influenza; interferon-alpha and -beta; and antihelminthic agents. Pending the evaluation of these agents, no convincing results are available that could lead to safe and curative [1] . The usefulness of information found in these reviews is highly questionable, as these papers always cite the same publications and do not bring any new perspective.

Their benefit for the readership does raise questions compared to the surrounding noise and confusion they generate. Desperate or anxious prescribers could be tempted by doubtful individual decisions based on mistaken beliefs or risky bets, ignoring adverse events or unpredictable reactions of nonvalidated therapies. Moreover, physicians should also understand that the inclusion of some drugs in national treatment guidelines or emergency authorisation by federal agencies is not a guarantee of quality or efficacy.

SARS-CoV-2 has been around for only a few months, during which the message has been that no therapies have been shown to be effective, and supportive care remains the best and only approved management [2, 3] . The research of therapeutics against this new threat is at its very beginning.

Prescribers cannot be satisfied with the mediocre results currently published from neither open-cohort nor high-quality randomised studies [4] . Today, the most common criteria for evaluating these new A new and worrisome situation is the deleterious availability of pre-reviewed manuscripts, leading to an implausible background noise in the scientific field, not taking into account the additional and detrimental effects of social media. Unfortunately, international media stay tuned to the latest breaking news items, reinforcing confusion. Nevertheless, live mapping of ongoing research and evidence synthesis, such as independent collaborative websites (metaevidence.org) or institutional websites (covid-nma.com), may help clinicians stay up to date on recently updated projects.

In summary, the strength of this review of Sander et al. lies in its honesty and accuracy in the analysis of the potential, but unproven, therapeutic tools for COVID-19.

Pharmacologic treatments for Coronavirus disease 2019 (COVID-19) A review

Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie à SARS-CoV2. SRLF-SFAR-SFMU-GFRUP-SPILF-SPLF mise en oeuvre avec la mission COREB nationale

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Adaptive designs in clinical trials: why use them, and how to run and report them